The IPO is now live and pricing is expected within 1-2 days. Monitor for the final IPO price and first-day trading performance. The $60 million indication of interest from existing investors provides a floor for demand.
Price Chart
Executive Summary
Iambic Therapeutics' IPO registration (S-1, File No. 333-299057) was declared effective by the SEC on October 14, 2026. The company is offering 9,375,000 shares of common stock at an expected price range of $15.00-$17.00 per share, with an underwriter option for an additional 1,406,250 shares. The IPO is expected to close shortly, with shares listing on Nasdaq under ticker 'IAM'.
Key Facts
- IPO registration declared effective on October 14, 2026
- Offering 9,375,000 shares of common stock
- Expected IPO price range: $15.00-$17.00 per share
- Underwriters have a 30-day option to purchase up to 1,406,250 additional shares
- Indications of interest from ARK Investment Management and Duquesne Family Office for up to $60.0 million in aggregate
- Shares to list on The Nasdaq Global Select Market under symbol 'IAM'
- Company qualifies as an emerging growth company and smaller reporting company
Financial Impact
Gross proceeds from the IPO at the midpoint of the price range ($16.00/share) would be approximately $150 million from the primary offering, with potential for an additional ~$22.5 million if the underwriter option is fully exercised.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- IPO pricing below the indicated range could signal weak demand
- Post-IPO lockup expiration and potential insider selling
- Clinical trial failure risk for pipeline candidates
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003244 |
| Document: 9999999995-26-003244-index.html | 9999999995-26-003244 |
| Document: 9999999995-26-003244.txt | 9999999995-26-003244 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Insider Buy | $16.01 $15.80 | ▼ −1.31% | ▼ −1.84% | $14.41 (−9.99%) |
Oct 16, 2026 10d ago | 8-K | $16.34 $16.01 | ▼ −2.02% | ▼ −2.35% | $14.41 (−11.81%) |
Oct 15, 2026 11d ago | 424B4 | $23.81 $16.34 | ▼ −31.37% | ▼ −31.80% | $14.41 (−39.48%) |
Oct 15, 2026 12d ago | EFFECT | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers